Emmdara 50 Injection 1's

Emmdara 50 Injection 1's belongs to a group of anticancer medicines called purine analogue used in the treatment of chronic lymphocytic leukaemia. Leukaemia, also known as blood cancer, is a cancer of blood cells or blood-forming tissues. It causes excessive production of immature white blood cells by the bone marrow and reduces the body’s ability to fight infections. 

Emmdara 50 Injection 1's contains Fludarabine, which works by inhibiting DNA synthesis (responsible for DNA elongation, synthesis, and repair) in cancer cells by interfering with the ribonucleotide reductase and DNA polymerase enzymes. Thus, Emmdara 50 Injection 1's slows or stops the growth of cancer cells in the body.

Emmdara 50 Injection 1's may cause certain side effects such as fever, chills, hair loss, depression, fatigue, vomiting, nausea, headache, cough, constipation, oedema, weakness, and pain at the site of injection. Most of these side effects of Emmdara 50 Injection 1's do not require medical attention and gradually resolve over time. However, if the side effects persist or worsen, please seek medical help. A trained healthcare professional will administer Emmdara 50 Injection 1's. Hence, do not self-administer.

If you are allergic to Emmdara 50 Injection 1's, inform your doctor and avoid taking it. Inform your doctor about your complete medical and medication history before starting treatment with Emmdara 50 Injection 1's. Emmdara 50 Injection 1's is contraindicated for pregnant women and breastfeeding women due to serious embryo-fetal toxicity. Hence, consult your doctor if you are pregnant, planning to become pregnant or breastfeeding. Let the doctor know if you have/had kidney or liver disease, hemolytic anaemia, severe bone marrow suppression, thrombocytopenia, or neutropenia before starting the treatment, as it may worsen your condition. Inform your doctor if you have received any vaccination before starting the treatment.

Emmdara 50 Injection 1's contains Fludarabine, which belongs to the class of purine analogues. It works by inhibiting DNA synthesis (responsible for DNA elongation, synthesis, and repair) in cancer cells by interfering with the ribonucleotide reductase and DNA polymerase enzymes. Thus, Emmdara 50 Injection 1's stops the multiplication of abnormal cells and causes the death of cancer cells.

• Vomiting
• Nausea
• Mouth ulcers
• Loss of appetite
• Constipation
• Weakness
• Injection site reactions
• Pain at the site of injection
• Headache
• Hair loss

If you are allergic to Emmdara 50 Injection 1's, inform your doctor and avoid taking it. Inform your doctor about your complete medical and medication history before starting treatment with Emmdara 50 Injection 1's. Emmdara 50 Injection 1's is contraindicated for pregnant women and breastfeeding women due to serious embryo-fetal toxicity. Hence, consult your doctor if you are pregnant, planning to become pregnant or breastfeeding. Let the doctor know if you have/had kidney or liver disease, haemolytic anaemia, severe bone marrow suppression, thrombocytopenia (low number of platelets), or neutropenia (low white blood cells) before starting the treatment, as it may worsen your condition. If you are about to receive any vaccinations, inform your doctor that you are taking Emmdara 50 Injection 1's as it may cause infection.

• PENTOSTATIN

• Regular blood tests are recommended while receiving Emmdara 50 Injection 1's to monitor any signs of anemia, neutropenia and thrombocytopenia
• Emmdara 50 Injection 1's is contraindicated for use in combination with pentostatin due to the increased risk of severe pulmonary toxicity.

• Maintain a balanced diet including fruits and vegetables rich in nutrients and low-fat proteins like lean meats, fish and poultry.
• Drink plenty of water daily while taking the medication, as some cancer therapies may cause dehydration.
• Exercise regularly and maintain a healthy body weight.
• Regularly wash your hands and avoid contact with people having infections.
• Quit smoking.